Latest Viatris News & Updates

See the latest news and media coverage for Viatris. We track all announcements, press releases, and industry mentions in real time, all in one place.

Viatris

Global healthcare company

viatris.com

Headquarters: Pittsburgh, United States
Company type: Public company
Number of employees: 15,000+
Industry: Pharmaceuticals

Last updated Today

Latest news about Viatris

In short: Viatris secured FDA approval for the Gwyn Lo contraceptive patch, reported robust 2026 Q1 growth, and advanced its 2030 strategic vision.

Company announcements

July 29 Viatris

Viatris receives FDA approval for Gwyn Lo contraceptive patch

The patch offers low-dose estrogen once-weekly contraception with demonstrated efficacy and safety in clinical trials.

June 29 Viatris

Viatris announces positive Phase 3 results for VR-205

The study met primary and key secondary endpoints with a 33.75% UPCR reduction. Submission targeted by end of 2026.

May 18 Viatris

Viatris announces FDA acceptance of NDA for fast-acting meloxicam

The FDA set a PDUFA goal date of Dec. 27, 2026 for the non-opioid acute pain treatment.

May 7 Viatris

Viatris reports Q1 2026 financial results

Total revenues reached $3.5 billion, up 8% reported. Adjusted EBITDA hit $1.0 billion, up 10% operationally. Reaffirms full-year guidance.

Media coverage

July 29 GuruFocus

VTRS Looks 61.9% Overvalued on GF Value™ After FDA Nod for Gwyn

On July 29, 2026, Viatris Inc (NASDAQ: VTRS) announced FDA approval for Gwyn Lo, a new low-estrogen...

July 29 Medscape

FDA Approves New Once-Weekly Birth Control Patch Gwyn Lo

The FDA has approved Gwyn Lo (Viatris), a new birth control patch that uses low-dose estrogen to prevent pregnancy.

July 22 The Business Times

Trump sets 100% tariff on generic drugs with two-year delay

Generic drug makers will have two years to move production to the US or face a 100% import duty from August 2028...

July 21 MMM

FDA slaps Sanofi, Viatris with Untitled Letters over promotional emails, TV ad

In the latest pair of Untitled Letters, the FDA took issue with a Viatris TV ad and Sanofi's promotional emails.

Never miss news about Viatris

Track Viatris and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Viatris competitors & trending companies

Browse news for competitors to Viatris and other trending companies.